Regeneron presents an interesting investment case. Its valuation doesn't fully capture Dupixent's strength or its pipeline potential. Bears worry about Eylea's patent cliff, but this seems priced in.

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Suffolk, one of the most innovative and successful builders in the country, is expanding its California footprint with the ...